Zydus Lifesciences Limited (IN:ZYDUSLIFE)
:ZYDUSLIFE
Want to see IN:ZYDUSLIFE full AI Analyst Report?
ZYDUSLIFE Stock Chart & Stats
₹921.80
-₹19.40(-1.94%)
At close: 4:00 PM EST
₹921.80
-₹19.40(-1.94%)
Day’s Range― - ―
52-Week Range₹835.85 - ₹1,093.95
Previous CloseN/A
Volume1.39M
Average Volume (3M)33.86K
Market Cap
₹1.05T
Enterprise Value₹1.16T
Total Cash (Recent Filing)₹70.69B
Total Debt (Recent Filing)₹96.36B
Price to Earnings (P/E)22.1
Beta0.49
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.19%
Share Statistics
EPS (TTM)48.90
Shares Outstanding1,006,234,000
10 Day Avg. Volume33,597
30 Day Avg. Volume33,862
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)3.23
Price to Sales (P/S)3.23
P/FCF Ratio-72.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)41.84
Revenue Forecast (FY)₹306.42B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained top-line growth (10.8% in 2026 and multi-year compounding) indicates expanding market reach and product adoption across geographies. Durable revenue momentum supports ongoing R&D, scale benefits in manufacturing, and long-term reinvestment capacity.
Healthy Profitability & ROERobust margins and a return on equity near 18–19% reflect efficient operations and profitable product mix. Durable profitability provides internal funding for pipelines and cushions cyclical pressures, underpinning long-term shareholder returns and strategic flexibility.
Diversified Pharma Business & R&DA business model spanning branded formulations, generics for regulated markets, manufacturing and in-house R&D spreads commercial risk across channels and geographies. This structural diversification supports resilience and the ability to develop differentiated, higher-margin products over time.
Bears Say
Deteriorating Cash GenerationA sharp drop in operating cash flow and negative free cash flow materially weakens financial flexibility. Persistent cash conversion weakness limits capacity to self-fund R&D, capex or debt service, making the company more reliant on external financing during downturns.
Rapid Rise In LeverageA sudden increase in leverage reduces balance-sheet resilience and raises interest and refinancing risk. Higher debt limits strategic optionality, amplifies sensitivity to cash-flow swings, and may constrain investment in growth or delay product commercialization if cash remains weak.
Margin Compression / Earnings QualityMaterial margin decline signals cost pressure, adverse mix or one-off items that weaken earnings quality. Lower margins reduce the buffer against competitive or pricing pressure, limiting reinvestment and making long-term profitability more uncertain without clear structural fixes.
Zydus Lifesciences Limited News
ZYDUSLIFE FAQ
What was Zydus Lifesciences Limited’s price range in the past 12 months?
Zydus Lifesciences Limited lowest stock price was ₹835.85 and its highest was ₹1093.95 in the past 12 months.
What is Zydus Lifesciences Limited’s market cap?
Zydus Lifesciences Limited’s market cap is ₹1.05T.
When is Zydus Lifesciences Limited’s upcoming earnings report date?
Zydus Lifesciences Limited’s upcoming earnings report date is Aug 12, 2026 which is in 83 days.
How were Zydus Lifesciences Limited’s earnings last quarter?
Zydus Lifesciences Limited released its earnings results on May 19, 2026. The company reported ₹11 earnings per share for the quarter, beating the consensus estimate of ₹9.357 by ₹1.643.
Is Zydus Lifesciences Limited overvalued?
According to Wall Street analysts Zydus Lifesciences Limited’s price is currently Overvalued.
Does Zydus Lifesciences Limited pay dividends?
Zydus Lifesciences Limited pays a Annually dividend of ₹11 which represents an annual dividend yield of 1.19%. See more information on Zydus Lifesciences Limited dividends here
What is Zydus Lifesciences Limited’s EPS estimate?
Zydus Lifesciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zydus Lifesciences Limited have?
Zydus Lifesciences Limited has 1,006,234,000 shares outstanding.
What happened to Zydus Lifesciences Limited’s price movement after its last earnings report?
Zydus Lifesciences Limited reported an EPS of ₹11 in its last earnings report, beating expectations of ₹9.357. Following the earnings report the stock price went up 2.8%.
Which hedge fund is a major shareholder of Zydus Lifesciences Limited?
Currently, no hedge funds are holding shares in IN:ZYDUSLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.
Technical Analysis
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Mankind Pharma Ltd.
―
Torrent Pharmaceuticals Ltd
―